News for Sangamo Therapeutics Inc

TipRanks 139d

Biotech Alert: Searches spiking for these stocks today

TipRanks 141d

CompoSecure to spin off Resolute, EHang raises Q4 revenue view; Morning Buzz

TipRanks 141d

Sangamo Biosciences: Buy Rating Affirmed Amid Pipeline Potential and Strategic Partnerships

TipRanks 141d

Sangamo selloff on Pfizer decision overdone, says H.C. Wainwright

TipRanks 141d

Sangamo price target lowered to $3 from $7 at Jefferies

TipRanks 141d

Sangamo Biosciences: Overcoming Setbacks with Strategic Partnerships and Fabry Program Potential

Seeking Alpha 141d

Why did Pfizer's exit from gene therapy program hit Sangamo hard?

Seeking Alpha 141d

Biggest stock movers Tuesday: VSTM, DAVE, SGMO and more

TipRanks 141d

Morning Movers: EHang jumps following guidance raise

TipRanks 141d

Sangamo price target lowered to $2 from $3 at Wells Fargo

TipRanks 141d

Sangamo Biosciences: Hold Rating Amidst Funding Challenges and Strategic Uncertainty

TipRanks 141d

Sangamo cash an overhang after Pfizer termination, says Truist

TipRanks 141d

TD Cowen ‘disappointed’ Pfizer ended Sangamo collaboration

TipRanks 142d

Sangamo Biosciences: Promising Investment Despite Hem A Partnership Setback with Pfizer

TipRanks 142d

Sangamo decline on Pfizer collaboration decision ‘overdone’, says Barclays

TipRanks 142d

Barclays Reaffirms Their Buy Rating on Sangamo Biosciences (SGMO)

TipRanks 142d

Closing Bell Movers: CompoSecure gains 5% on Resolute Holdings spinoff

TipRanks 142d

Sangamo Biosciences Faces Pfizer Collaboration Termination

Seeking Alpha 142d

Sangamo plunges 38% after Pfizer ends agreement on hemophilia A gene therapy

TipRanks 142d

Sangamo down 31% at $1.61 after Pfizer decision to terminate collaboration

TipRanks 142d

Sangamo to regain rights to giroctocogene fitelparvovec from Pfizer

TipRanks 152d

Sangamo Biosciences: Strategic Neurology Advancements and Financial Growth Potential with Astellas Partnership

Seeking Alpha 153d

Biggest stock movers Thursday: ACN, MU, MESO, and more

Seeking Alpha 153d

Sangamo spikes on Astellas licensing deal for gene therapy tech

TipRanks 153d

Sangamo to receive $20M from Astellas Pharma in capsid license agreement

TipRanks 154d

Biotech Alert: Searches spiking for these stocks today

Seeking Alpha 156d

Sangamo surges 24% after Roche ends development of hemophilia A gene therapy

TipRanks 159d

TD Cowen Sticks to Their Buy Rating for Sangamo Biosciences (SGMO)

TipRanks 159d

Sangamo Biosciences: Strategic Growth and Advancing Pipeline Drive Buy Rating

TipRanks 159d

Sangamo upgraded to Buy from Hold at Truist

TipRanks 162d

Promising Trial Results and Strategic Partnerships Drive Buy Rating for Sangamo Biosciences

TipRanks 162d

Sangamo Biosciences’ Legal Victory and Hemophilia Trial Success

TipRanks 183d

Closing Bell Movers: Keysight up 9% after Q4 earnings beat

Seeking Alpha 183d

Sangamo stock climbs 12% post-market on FDA update for ST-503

TipRanks 183d

Sangamo gets FDA clearance of IND application for ST-503 in iSFN

TipRanks 183d

Sangamo up 11% at $2.17 on FDA clearing IND for ST-503

TipRanks 188d

Sangamo price target raised to $3 from $1 at Wells Fargo

TipRanks 188d

Sangamo Biosciences: Strategic Advancements and Collaborations Bolster Buy Rating

TipRanks 188d

Wells Fargo Gives a Hold Rating to Sangamo Biosciences (SGMO)

TipRanks 189d

Sangamo Biosciences: Mine Safety Regulations Pose No Risk to Operations

TipRanks 189d

Sangamo Biosciences: Promising Financial Position and Strategic FDA Alignment Drive Buy Rating

TipRanks 189d

Sangamo Biosciences: Buy Rating Supported by Promising Fabry Program Developments and Regulatory Alignment

TipRanks 189d

Sangamo price target raised to $9 from $3 at Barclays

TipRanks 189d

RBC Capital Remains a Hold on Sangamo Biosciences (SGMO)

TipRanks 190d

Sangamo Therapeutics Reports Strong Q3 2024 Growth

Seeking Alpha 190d

Sangamo Therapeutics files for mixed shelf offering

TipRanks 190d

Sangamo files $500M mixed securities shelf

Seeking Alpha 190d

Sangamo Therapeutics Q3 beats propel stock 5% higher

TipRanks 190d

Sangamo reports Q3 EPS 4c, consensus (3c)

Seeking Alpha 190d

Sangamo Therapeutics GAAP EPS of $0.04 beats by $0.08, revenue of $49.41M beats by $24.34M

	
		OSZAR »